Concepedia
Statistics
Publications
17
Citations
647
H-Index
13
Active since
2020
Affiliations
University of Michigan(Current)
Genmab (United States)
AbbVie (United States)
University of Colorado Denver
Icahn School of Medicine at Mount Sinai
Yasmin Karimi is an author at University of Michigan specializing in oncology, medicine, and immunotherapy.
Publications per year
2020–2025
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L. Crombie, Tara Graff, Lorenzo Falchi et al. · Blood · 2024 · 131 citations · Full text
Life Sciences, Immunology, Oncology +14
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières et al. · Leukemia · 2024 · 119 citations · Full text
Medicine, Oncology, Hematologic Oncology +7
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson et al. · Journal of the National Comprehensive Cancer Network · 2023 · 117 citations · Full text
Medicine, Hematology, Oncology +17
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua Brody, Judit Jørgensen, David Belada et al. · Blood · 2025 · 48 citations · Full text
Medicine, Oncology, Pharmacotherapy +13
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Adam Zayac, Daniel J. Landsburg, Mitchell E. Hughes et al. · Blood Advances · 2023 · 32 citations · Full text
Medicine, Hematology, Oncology +16
1–5 of 17